Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Topoisomerase II inhibitor
DRUG CLASS:
Topoisomerase II inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
doxorubicin hydrochloride (87)
etoposide IV (53)
etoposide oral (33)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
MM-302 (4)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
RTA 744 (1)
amsacrine (0)
amrubicin (0)
mitoxantrone liposomal (0)
H-ferritin–nanocaged doxorubicin (0)
HF158K1 (0)
MNPR-202 (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
idronoxil (0)
INNO-206 (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
doxorubicin liposomal (0)
AVA6000 (0)
2X-111 (0)
NP-ACT D (0)
valrubicin (0)
doxorubicin hydrochloride (87)
etoposide IV (53)
etoposide oral (33)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
MM-302 (4)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
RTA 744 (1)
amsacrine (0)
amrubicin (0)
mitoxantrone liposomal (0)
H-ferritin–nanocaged doxorubicin (0)
HF158K1 (0)
MNPR-202 (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
idronoxil (0)
INNO-206 (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
doxorubicin liposomal (0)
AVA6000 (0)
2X-111 (0)
NP-ACT D (0)
valrubicin (0)
›
Associations
(323)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
No biomarker
Testicular Cancer
No biomarker
Testicular Cancer
etoposide IV
Sensitive: A1 - Approval
etoposide IV
Sensitive
:
A1
etoposide IV
Sensitive: A1 - Approval
etoposide IV
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
pixantrone
Sensitive: A1 - Approval
pixantrone
Sensitive
:
A1
pixantrone
Sensitive: A1 - Approval
pixantrone
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
non-pegylated liposomal doxorubicin
Sensitive: A1 - Approval
non-pegylated liposomal doxorubicin
Sensitive
:
A1
non-pegylated liposomal doxorubicin
Sensitive: A1 - Approval
non-pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Kaposi Sarcoma
No biomarker
Kaposi Sarcoma
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.